Regeneron Earnings Call Highlights Durable Growth Engine

Regeneron Pharmaceuticals ((REGN)) has held its Q1 earnings call. Read on for the main highlights of the call.

Regeneron Pharmaceuticals’ latest earnings call struck an upbeat tone as management highlighted strong double-digit growth in revenue and earnings alongside rapid uptake of key growth drivers. Executives acknowledged product-specific and regulatory headwinds, but framed them as manageable against a backdrop of robust pipeline progress, high margins and a fortress balance sheet.

Strong Top- and Bottom-Line Growth

Regeneron reported Q1 2026 revenue of $3.6 billion, up 19% year over year, underscoring the company’s ability to grow even as certain legacy products face pressure. Non-GAAP diluted EPS climbed 15% to $9.47, with net income reaching $1.0 billion, confirming that profit growth is broadly keeping pace with sales.

DUPIXENT Continued Momentum

DUPIXENT remained the company’s primary engine, with global net sales rising 31% in constant currency to $4.9 billion for the quarter. Management emphasized that the franchise is now tracking at nearly $20 billion in annualized global net sales, reflecting broad demand across indications and geographies.

EYLEA HD Rapid U.S. Adoption

EYLEA HD continued its rapid ramp in the United States, with net product sales up 52% year over year to $468 million in Q1. Combined U.S. EYLEA and EYLEA HD sales totaled $942 million, and physician demand for the high-dose formulation increased roughly 10% sequentially, with similar unit growth targeted for Q2.

Libtayo Growth

Libtayo also posted standout growth, with global product sales rising 54% year over year to $438 million. Uptake in advanced cutaneous squamous cell carcinoma and advanced non-small cell lung cancer led the gains, complemented by early contributions from the adjuvant CSCC indication.

Pipeline and Regulatory Progress

The call highlighted a series of pipeline milestones, including FDA approval of Otarmeni, a gene therapy for genetic hearing loss that Regeneron plans to provide at no cost. Positive Phase III data for cemdisiran in generalized myasthenia gravis and priority FDA review for garetosmab, along with promising weight-loss data from olatorepatide in China, reinforced the company’s long-term growth story.

Sanofi Collaboration and Other Revenue Strength

Revenues from the Sanofi collaboration reached $1.6 billion in Q1, with Regeneron’s share of collaboration profits rising 42% versus last year. Other revenue more than doubled to $171 million, helped by ARCALYST and Ilaris royalties, and the Sanofi development balance is expected to be fully repaid by the end of Q2, after which Regeneron will book its full profit share.

Balance Sheet and Capital Allocation

The company generated $848 million in free cash flow during the quarter and ended Q1 with $15.8 billion of cash and marketable securities net of debt. Regeneron repurchased $800 million of stock and received board approval for a new $3.0 billion buyback program, leaving roughly $3.4 billion available for future repurchases.

High Non-GAAP Gross Margins

Non-GAAP gross margin on net product sales remained a key strength at 86% in Q1, aided by a favorable product mix and high-margin assets like DUPIXENT. Management positioned this margin profile as a competitive advantage that supports heavy reinvestment in R&D and commercial launches while still delivering solid earnings.

EYLEA Base Product Decline and Inventory Dynamics

Against the high-dose momentum, legacy EYLEA U.S. net sales dropped 36% year over year to $473 million as patients shifted to EYLEA HD and competitors, with affordability also weighing on demand. The company expects wholesaler and inventory dynamics to trim about $20 million from EYLEA net sales in Q2 and anticipates mid- to high-teens demand declines ahead of potential biosimilars in the second half.

Regulatory Uncertainty for EYLEA HD Prefilled Syringe

Regeneron faced a regulatory setback when the FDA did not act by the April PDUFA date on its application for a second contract manufacturer for the EYLEA HD prefilled syringe. After a reinspection at the manufacturing partner, the filings remain pending, and while management still expects an FDA decision on one or both applications this quarter, the timing adds near-term uncertainty for the franchise.

Manufacturing Interruption Impacting GAAP Margins

A temporary production interruption at the company’s Limerick, Ireland site weighed on reported GAAP gross margin, which came in at 76% in Q1. With full bulk manufacturing expected to resume by the end of Q2, management trimmed full-year GAAP gross margin guidance to 77%–78%, indicating the impact should be transitory.

Exposure to Competitive and Pricing Pressures

Management underscored growing competitive pressures and patient affordability issues impacting EYLEA, which are expected to intensify with potential biosimilar entries later in 2026. The company has also entered a Most Favored Nation pricing arrangement with the U.S. government for Medicare, which may pressure pricing but could help sustain access for key therapies.

Near-Term Regulatory and Clinical Readouts Still Pending

Several important regulatory events and clinical readouts remain ahead, including an FDA decision on cemdisiran in Q4 and a PDUFA date for garetosmab in August. Results from a registrational program in PNH are expected late in Q4, leaving part of Regeneron’s near-term upside tied to how these catalysts play out.

R&D and SG&A Investment Levels

Regeneron continues to spend heavily to support its pipeline and launches, with R&D expenses at $1.4 billion and SG&A at $560 million in Q1. While these investments are strategic and aimed at securing future growth, they represent sizeable cost commitments that could pressure GAAP results if key programs or launches underperform.

Guidance and Outlook

Looking ahead, Regeneron made only modest changes to its 2026 outlook, mainly trimming GAAP gross margin guidance to 77%–78% as the Limerick manufacturing issue resolves by the end of Q2. Management also highlighted the expected full repayment of the Sanofi development balance by Q2, allowing Regeneron to recognize its full profit share from Q3 and underpinning confidence in continued revenue and earnings growth.

Regeneron’s earnings call painted the picture of a company balancing short-term challenges with strong long-term fundamentals. With DUPIXENT, EYLEA HD and Libtayo driving growth, a deep pipeline advancing through late-stage milestones and a sizeable buyback powered by a strong balance sheet, investors are being asked to look beyond EYLEA headwinds and regulatory noise toward a broader, diversified growth story.